v**********m
发帖数: 5516 | 6 At this price, I will stay away from this company.
From its income sheets during 2010-2012, it does not look like a promising
stock, though it may be a promising company.
===================================================
FROM SEEKING ALPHA
http://seekingalpha.com/article/1319051-1-software-1-biotech-an
Insider selling by insider (last 30 days)
Gajus Worthington sold 10,000 shares on April 1 pursuant to a Rule 10b5-
1 trading plan. Gajus Worthington currently controls 185,159 shares or 0.7%
of the company. Gajus Worthington is a Co-Founder of Fluidigm Corporation
and has served as President and Chief Executive Officer and a Director since
the company's inception in June 1999.
William Smith sold 5,000 shares on April 1 pursuant to a Rule 10b5-1
trading plan. William Smith currently holds 2,510 options or less than 0.1%
of the company. William Smith has served as Executive Vice President, Legal
Affairs since January 2012.
Robert Jones sold 7,000 shares on March 18-28 pursuant to a Rule 10b5-1
trading plan. Robert Jones currently holds 10,319 options or less than 0.1%
of the company. Robert Jones has served as Executive Vice President,
Research and Development since August 2005.
Vikram Jog sold 5,661 shares on March 18-28 pursuant to a Rule 10b5-1
trading plan. Vikram Jog currently holds 2,487 options or less than 0.1% of
the company. Vikram Jog has served as Chief Financial Officer since February
2008.
Mai Yow sold 30,000 shares on March 4 pursuant to a Rule 10b5-1 trading
plan. Mai Yow currently holds 573 options or less than 0.1% of the company.
Mai Yow has served as Executive Vice President, Worldwide Manufacturing of
Fluidigm Singapore Pte. Ltd., the company's Singapore subsidiary, since
January 2012.
Insider selling by calendar month
Here is a table of Fluidigm's insider trading activity by calendar month.
Month Insider selling / shares Insider buying / shares
April 2013 15,000 0
March 2013 62,661 0
February 2013 33,306 0
January 2013 51,122 0
There have been 162,089 shares sold and zero shares purchased this year.
Financials
The company reported the full year 2012 financial results on February 12
with the following highlights:
Revenue $52.3 million
Net loss $19.0 million
Cash $80.0 million
Outlook
The company is projecting 2013 total revenue growth guidance to be 22%-26%
over 2012. Historically, Fluidigm's product revenues have tended to be
lowest in the first quarter of the year and highest in the fourth quarter of
the year. Fluidigm expects this trend to continue in 2013.
Competition
Fluidigm's competitors include Affymetrix (AFFX), Illumina (ILMN) and Life
Technologies Corporation (LIFE). Here is a table comparing these companies.
Company
FLDM AFFX ILMN LIFE Industry Average (Scientific & Technical
Instruments)
Market Cap: 473.13M 333.95M 6.76B 11.20B 19.19M
Employees: 278 1,100 2,400 10,000 5.86K
Qtrly Rev Growth (yoy): 0.21 0.30 0.24 -0.01 0.00
Revenue: 52.33M 295.62M 1.15B 3.80B 654.65K
Gross Margin: 0.71 0.55 0.69 0.66 0.60
EBITDA: -15.93M 15.29M 327.76M 1.20B -1.76M
Operating Margin: -0.35 -0.07 0.23 0.21 0.25
Net Income: -19.02M -10.70M 151.25M 430.86M N/A
EPS: -0.86 -0.15 1.13 2.40 1.56
P/E: N/A N/A 48.26 27.37 N/A
PEG (5 yr expected): -1.11 2.04 1.96 1.52 N/A
P/S: 9.04 1.13 5.89 2.95 29.32
Fluidigm is trading at a higher P/S multiple than its direct competitors.
My analysis
There have been six insider sell transactions and there have not been any
insider buy transactions during the last 30 days. The company has a book
value of $4.02 per share. Before entering short this stock, I would like to
get a bearish confirmation from the Point and Figure chart. The three main
reasons for the proposed short entry are negative earnings, relatively high
P/S ratio and the intensive insider selling activity.
10000
【在 p****t 的大作中提到】
: http://investors.fluidigm.com/
: 本人WSN，对股票没什么经验，看好上面的这个公司的技术和前景，准备买$5000-10000
: 的股票长期放着，LD也说了，赔了算了。想请教一下可行性。另外，该怎么具体操作？
: 先谢谢啦！
|
